You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Metastases

Docetaxel for the treatment of hormone-refractory metastatic prostate cancer

  • Technology appraisal guidance
  • Reference number: TA101
  • Published:  28 June 2006
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Appendix B: proposal paper presented to the Institute's Guidance Executive

Appendix B: proposal paper presented to the Institute's Guidance Executive Appendix B: proposal paper presented to the Institute's Guidance Executive
05 March 2012
(114.07 Kb 33 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 02 March 2012

Back to top